Results of standard chemotherapy in ovarian cancer are hampered by the development of
drug resistance leading to disease recurrence. This prompted interest in the development of …

The treatment of ovarian cancer remains challenging as the majority of patients will relapse
and die from their disease despite successful first-line treatment. New treatment strategies …

The last five years has seen a major expansion in the number of clinical trials with molecular
targeted agents in ovarian cancer. Most of the studies are with anti-angiogenic agents. This …

(1) Background: Among new anti-angiogenesis agents being developed and ever-changing
guidelines indications, the question of the benefits/safety ratio remains unclear.(2) Methods …

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy in adult women.
The most easily identifiable riskfactor is a strong family history of either ovarian or breast …

Background The 5-year survival of ovarian cancer has slowly increased but to date much of
this has been due to the use of more lines of treatment rather than better first-line therapy. In …

Introduction: Patients with epithelial ovarian cancer (EOC) have a high rate of recurrence,
and overall survival remains at∼ 25%. There is a need for new treatments that can increase …

Introduction: Epithelial ovarian cancer (EOC) is the fourth commonest cause of female
cancer death in the developed world. Although progress in treatment has improved …

Angiogenesis is known to play an important role in normal ovarian physiology as well as in
growth and progression of ovarian cancer. The first FDA approval of bevacizumab in 2004 …

Background Angiogenesis inhibitors showed activity in ovarian cancer, but preliminary data
could not accurately reflect the survival benefit. We thus did a systematic review and meta …